ID

40995

Descripción

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01202591

Link

https://clinicaltrials.gov/show/NCT01202591

Palabras clave

Versiones (1)
  1. 9/6/20 9/6/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

9 de junio de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility FGFR Inhibition, Pharmacokinetics, Biomarkers NCT01202591

Inglés

Eligibility FGFR Inhibition, Pharmacokinetics, Biomarkers NCT01202591

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)
Descripción

Postmenopausal state | Bilateral oophorectomy | Amenorrhea Duration

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0278321
UMLS CUI [3,1]
C0002453
UMLS CUI [3,2]
C0449238
histological confirmation of breast cancer with documented er+ receptor status
Descripción

Oestrogen receptor positive breast cancer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2938924
safety run-in: relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal ai and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal al
Descripción

Relapse | Hormone Therapy Adjuvant Completed | Anti-Inflammatory Agents, Non-Steroidal | Tamoxifen | Disease Progression | Status post First line Hormone Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0035020
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1522673
UMLS CUI [2,3]
C0205197
UMLS CUI [3]
C0003211
UMLS CUI [4]
C0039286
UMLS CUI [5]
C0242656
UMLS CUI [6,1]
C0231290
UMLS CUI [6,2]
C1708063
UMLS CUI [6,3]
C0279025
rand phase iia: received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal ai or tamoxifen or a combination of both). chemotherapy administered in the adjuvant setting is permitted.
Descripción

Hormone Therapy Quantity Metastatic Setting | Relapse | Hormone Therapy Adjuvant Completed | Anti-Inflammatory Agents, Non-Steroidal | Tamoxifen | Combined Modality Therapy | Chemotherapy Adjuvant Setting allowed

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C4085632
UMLS CUI [2]
C0035020
UMLS CUI [3,1]
C0279025
UMLS CUI [3,2]
C1522673
UMLS CUI [3,3]
C0205197
UMLS CUI [4]
C0003211
UMLS CUI [5]
C0039286
UMLS CUI [6]
C0009429
UMLS CUI [7,1]
C0392920
UMLS CUI [7,2]
C4084850
UMLS CUI [7,3]
C0683607
rand phase iia: mandatory provision of tumour sample to confirm fgfr1 polysomy or gene amplification. at least one measurable lesion that can be accurately assessed by ct/mri/x-ray at baseline and follow up visits
Descripción

Tumor tissue sample mandatory | FGFR1 Polysomy | FGFR1 Gene Amplification | Measurable lesion Quantity CT | Measurable lesion Quantity MRI | Measurable lesion Quantity X-Ray

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C1514873
UMLS CUI [2,1]
C0919509
UMLS CUI [2,2]
C1514212
UMLS CUI [3,1]
C0919509
UMLS CUI [3,2]
C0017256
UMLS CUI [4,1]
C1513041
UMLS CUI [4,2]
C1265611
UMLS CUI [4,3]
C0040405
UMLS CUI [5,1]
C1513041
UMLS CUI [5,2]
C1265611
UMLS CUI [5,3]
C0024485
UMLS CUI [6,1]
C1513041
UMLS CUI [6,2]
C1265611
UMLS CUI [6,3]
C0043299
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase iia), or any agent known to inhibit fgfrs.
Descripción

Exposure to Exemestane | Exposure to Fulvestrant | Exposure to FGFR Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0851344
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0935916
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C0060369
UMLS CUI [3,3]
C1999216
more than 1 prior regimen of chemotherapy for breast cancer
Descripción

Prior Chemotherapy Quantity Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0678222
ecg recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction
Descripción

Abnormal heart rate Electrocardiography | Cardiac Arrhythmia Electrocardiography | Abnormal cardiac conduction Electrocardiography

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1744601
UMLS CUI [1,2]
C1623258
UMLS CUI [2,1]
C0003811
UMLS CUI [2,2]
C1623258
UMLS CUI [3,1]
C0232219
UMLS CUI [3,2]
C1623258
history of hypersensitivity to active or inactive excipients of azd4547 or exemestane (safety run-in ) or fulvestrant (randomized phase), including castor oil, or drugs with a similar chemical structure or class to azd4547 or exemestane or fulvestrant.
Descripción

Hypersensitivity Excipient AZD4547 | Hypersensitivity Excipient Exemestane | Hypersensitivity Excipient Fulvestrant | Hypersensitivity Excipient Castor Oil | Hypersensitivity Drug Similar

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0015237
UMLS CUI [1,3]
C2981795
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0015237
UMLS CUI [2,3]
C0851344
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0015237
UMLS CUI [3,3]
C0935916
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0015237
UMLS CUI [4,3]
C0007343
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C1254351
UMLS CUI [5,3]
C2348205
randomized phase iia: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks
Descripción

Hemorrhage | Blood Clotting | Fulvestrant Injection Buttocks Preventing

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019080
UMLS CUI [2]
C0302148
UMLS CUI [3,1]
C0935916
UMLS CUI [3,2]
C1828121
UMLS CUI [3,3]
C0006497
UMLS CUI [3,4]
C1292733
Volver a la parte superior de la página

Similar models

Eligibility FGFR Inhibition, Pharmacokinetics, Biomarkers NCT01202591

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state | Bilateral oophorectomy | Amenorrhea Duration
Item
post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)
boolean
C0232970 (UMLS CUI [1])
C0278321 (UMLS CUI [2])
C0002453 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Oestrogen receptor positive breast cancer
Item
histological confirmation of breast cancer with documented er+ receptor status
boolean
C2938924 (UMLS CUI [1])
Relapse | Hormone Therapy Adjuvant Completed | Anti-Inflammatory Agents, Non-Steroidal | Tamoxifen | Disease Progression | Status post First line Hormone Therapy
Item
safety run-in: relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal ai and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal al
boolean
C0035020 (UMLS CUI [1])
C0279025 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
C0003211 (UMLS CUI [3])
C0039286 (UMLS CUI [4])
C0242656 (UMLS CUI [5])
C0231290 (UMLS CUI [6,1])
C1708063 (UMLS CUI [6,2])
C0279025 (UMLS CUI [6,3])
Hormone Therapy Quantity Metastatic Setting | Relapse | Hormone Therapy Adjuvant Completed | Anti-Inflammatory Agents, Non-Steroidal | Tamoxifen | Combined Modality Therapy | Chemotherapy Adjuvant Setting allowed
Item
rand phase iia: received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal ai or tamoxifen or a combination of both). chemotherapy administered in the adjuvant setting is permitted.
boolean
C0279025 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C4085632 (UMLS CUI [1,3])
C0035020 (UMLS CUI [2])
C0279025 (UMLS CUI [3,1])
C1522673 (UMLS CUI [3,2])
C0205197 (UMLS CUI [3,3])
C0003211 (UMLS CUI [4])
C0039286 (UMLS CUI [5])
C0009429 (UMLS CUI [6])
C0392920 (UMLS CUI [7,1])
C4084850 (UMLS CUI [7,2])
C0683607 (UMLS CUI [7,3])
Tumor tissue sample mandatory | FGFR1 Polysomy | FGFR1 Gene Amplification | Measurable lesion Quantity CT | Measurable lesion Quantity MRI | Measurable lesion Quantity X-Ray
Item
rand phase iia: mandatory provision of tumour sample to confirm fgfr1 polysomy or gene amplification. at least one measurable lesion that can be accurately assessed by ct/mri/x-ray at baseline and follow up visits
boolean
C0475358 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0919509 (UMLS CUI [2,1])
C1514212 (UMLS CUI [2,2])
C0919509 (UMLS CUI [3,1])
C0017256 (UMLS CUI [3,2])
C1513041 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0040405 (UMLS CUI [4,3])
C1513041 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C0024485 (UMLS CUI [5,3])
C1513041 (UMLS CUI [6,1])
C1265611 (UMLS CUI [6,2])
C0043299 (UMLS CUI [6,3])
Item Group
C0680251 (UMLS CUI)
Exposure to Exemestane | Exposure to Fulvestrant | Exposure to FGFR Inhibitor
Item
prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase iia), or any agent known to inhibit fgfrs.
boolean
C0332157 (UMLS CUI [1,1])
C0851344 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0935916 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C0060369 (UMLS CUI [3,2])
C1999216 (UMLS CUI [3,3])
Prior Chemotherapy Quantity Breast Carcinoma
Item
more than 1 prior regimen of chemotherapy for breast cancer
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0678222 (UMLS CUI [1,3])
Abnormal heart rate Electrocardiography | Cardiac Arrhythmia Electrocardiography | Abnormal cardiac conduction Electrocardiography
Item
ecg recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction
boolean
C1744601 (UMLS CUI [1,1])
C1623258 (UMLS CUI [1,2])
C0003811 (UMLS CUI [2,1])
C1623258 (UMLS CUI [2,2])
C0232219 (UMLS CUI [3,1])
C1623258 (UMLS CUI [3,2])
Hypersensitivity Excipient AZD4547 | Hypersensitivity Excipient Exemestane | Hypersensitivity Excipient Fulvestrant | Hypersensitivity Excipient Castor Oil | Hypersensitivity Drug Similar
Item
history of hypersensitivity to active or inactive excipients of azd4547 or exemestane (safety run-in ) or fulvestrant (randomized phase), including castor oil, or drugs with a similar chemical structure or class to azd4547 or exemestane or fulvestrant.
boolean
C0020517 (UMLS CUI [1,1])
C0015237 (UMLS CUI [1,2])
C2981795 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0015237 (UMLS CUI [2,2])
C0851344 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C0015237 (UMLS CUI [3,2])
C0935916 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0015237 (UMLS CUI [4,2])
C0007343 (UMLS CUI [4,3])
C0020517 (UMLS CUI [5,1])
C1254351 (UMLS CUI [5,2])
C2348205 (UMLS CUI [5,3])
Hemorrhage | Blood Clotting | Fulvestrant Injection Buttocks Preventing
Item
randomized phase iia: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks
boolean
C0019080 (UMLS CUI [1])
C0302148 (UMLS CUI [2])
C0935916 (UMLS CUI [3,1])
C1828121 (UMLS CUI [3,2])
C0006497 (UMLS CUI [3,3])
C1292733 (UMLS CUI [3,4])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial